Kv1.5/IKur inhibitors represent a novel, atrial-selective pharmacological target for the treatment of atrial fibrillation, highlighting the need for Phase 3 clinical trials to establish efficacy and safety.
Answers are grounded in this paper and cite their sources.
Does not support clinical use of Kv1.5 modulators in AF; leaves open their atrial-selective potential pending Phase 3 efficacy and safety data.
There is a clear unmet medical need for new pharmacologic therapies for the treatment of atrial fibrillation (AF) with improved efficacy and safety. This article reviews the development of new and novel Kv1.5/ultra-rapid delayed-rectifier current (I Kur) inhibitors and presents evidence that Kv1.5 modulation provides an atrial-selective mechanism for treating AF. Academia and industry have invested heavily in Kv1.5 (>500 scientific publications and >50 patents published since 1993); however, to realize the full value of this therapeutic drug target, clinical efficacy and safety data are required for a selective Kv1.5 modulator. The reward for demonstrating clinical efficacy and safety in a pivotal Phase 3 trial, on regulatory approval, is "first in class" status.
No takes yet. Share an insight, caveat, or question.
Ford et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: